LYMPHOCYTE ACTIVATION GENE - 3 PROTEIN MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Lymphocyte Activation Gene - 3 Protein Market - Overview Lymphocyte Activation Gene - 3 Protein Market Drivers Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global Lymphocyte Activation Gene - 3 Protein Market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. Immune checkpoint receptors such as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene - 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene - 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. Browse Research Reports: https://www.coherentmarketinsights.com/ongoinginsight/lymphocyte-activation-gene-3-protein-market-2027 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date - August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period. Manufacturers and researchers are focused on development of novel therapies that aid in treatment of cancer. High prevalence of cancer is expected to boost growth of the market. According to National Cancer Institute, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S., in 2018. The most common types of cancer are lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others. According to Cancer Research UK, 2015, around 54,900 new cases of breast cancer are registered in the UK, which account for 15% of all new cancer cases, annually.
However, uncertainty of clinical trials (as drugs may fail to show efficacy even in late phases of clinical trials) is expected to restrain the lymphocyte activation gene - 3 protein market growth over the forecast period. In cancers, lymphocyte activation gene - 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations.
There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2027 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Lymphocyte Activation Gene - 3 Protein Market Regional Insights North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017. High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene - 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base. Lymphocyte Activation Gene - 3 Protein Market Key Player Key players operating in the global lymphocyte activation gene - 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2027 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
© Coherent market Insights. All Rights Reserved